Study S002059

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06005012
Acronym: SAMARA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 120
Start: 2023-07-25
Primary completion: 2026-12-31
Lead sponsor: University of California, San Diego
Conditions: Fibrosis, Liver; Type 2 Diabetes Mellitus in Obese; Non-Alcoholic Fatty Liver Disease
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in fibrosis due to NAFLD [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.